Company news
Santhera Pharmaceuticals Holding Ag (SIX:SANN) news
Every Santhera Pharmaceuticals Holding Ag press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Santhera Expands Biomedica Agreement to Extend AGAMREE® (Vamorolone) Distribution Across Central Asia and the Caucasus
July 13, 2026
Santhera Announces Orphan Drug and Priority Review Designations for AGAMREE® (Vamorolone) in South Korea
June 2, 2026
Santhera Proposes Dr. Srishti Gupta as New Member of the Board of Directors
April 30, 2026
Santhera Announces Positive AIFA Board Decision on Reimbursement of AGAMREE® (vamorolone) in Italy
April 28, 2026
Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025
April 28, 2026
Santhera Receives Positive CHMP Opinion to Expand AGAMREE® (vamorolone) Use in Pediatric DMD Patients Aged Two and Older in the EU
April 27, 2026
Santhera Appoints Orlando Oliveira as Chief Executive Officer
April 23, 2026
Full Year 2025 Trading Update
March 12, 2026
Santhera Appoints Marc Clausse as Chief Commercial Officer to Lead Next Phase of Growth
March 10, 2026
AGAMREE® (vamorolone) Data Presented at MDA 2026 Confirm Comparable Long-Term Effectiveness for up to 8 Years of Treatment, with Clinical...
March 9, 2026
Santhera Announces Proposed Inclusion and Reimbursement of AGAMREE® (Vamorolone) within Spain’s National Health System for the Treatment ...
February 27, 2026
Santhera Appoints Stifel as Corporate Finance Advisor
February 10, 2026
Santhera Receives Swissmedic Approval of AGAMREE® (Vamorolone) for the Treatment of Duchenne Muscular Dystrophy
January 15, 2026
Santhera Pharmaceuticals : Receives Swissmedic Approval of AGAMREE® (Vamorolone) for the Treatment of Duchenne Muscular Dystrophy
January 14, 2026
Santhera Licenses AGAMREE® (Vamorolone) to Nxera Pharma in Japan, South Korea, Australia and New Zealand in a Deal Valued at up to USD 20...
January 8, 2026
Santhera Closes USD 13 Million Royalty Monetization Agreement
November 5, 2025
Five-year data of AGAMREE® (vamorolone) in patients with DMD show improved safety profile with comparable effectiveness to standard of ca...
November 4, 2025
Santhera Secures Agreement with Biomedica for the Distribution of AGAMREE® (Vamorolone) in Russia
October 9, 2025
Santhera Announces Approval in Canada for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
October 3, 2025
Santhera Provides Update on Convertible Bond Issued on 23 September 2025
September 25, 2025
Santhera Announces Half Year 2025 Financial Results and Provides Corporate Update
September 23, 2025
Santhera Secures CHF 20 Million Growth Funding to Accelerate Global AGAMREE® Rollout
September 23, 2025
Santhera Enters into Agreement with Ikris Pharma Network for the Distribution of AGAMREE® (Vamorolone) in India
August 29, 2025
Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries
August 19, 2025
Santhera extends Highbridge convertible bond to 30th September 2025
August 15, 2025
Santhera Secures Agreement with GEN for the Distribution of AGAMREE® (Vamorolone) in Türkiye
August 13, 2025
Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting
May 20, 2025
Santhera Publishes Agenda for its Annual General Meeting
April 29, 2025
Santhera Full Year Results for the Year Ended 31 December 2024
April 29, 2025
Santhera shares updates on commercial rollout of AGAMREE®
April 16, 2025
Santhera proposes Dr. Melanie Rolli as new member of Board of Directors
March 27, 2025
Santhera to share latest on commercial rollout of AGAMREE® and future strategic priorities at Capital Markets Day
March 24, 2025
Full Year Trading Update
March 4, 2025